Overview
FrançaisABSTRACT
The amorphous solid state has become a staple in the formulation of pharmaceutical compounds. This article looks at its applications and what differentiates it from the crystalline state. It reviews the benefits and issues of its implementation. Most of the article focuses on its solubility interest and discusses all aspects related to its physical and chemical stability, as well as its ability to stabilize fragile biomolecules. Complex amorphous systems combining several compounds (amorphous solid dispersions in polymers, co-amorphous systems, plasticizers and antiplasticizers, etc.) are the subject of particular attention.
Read this article from a comprehensive knowledge base, updated and supplemented with articles reviewed by scientific committees.
Read the articleAUTHOR
-
Marc DESCAMPS: UMET (Unité matériaux et transformations) UMR CNRS 8207, Bâtiment P5 (Physics), Université de Lille, Villeneuve-d'Ascq, France
INTRODUCTION
Awareness of the importance of amorphous materials in the pharmaceutical field is relatively recent. This disordered state of matter can be generated inadvertently during the manufacture of crystalline forms, following milling, atomization, compaction, granulation and other operations. However, its formation may be intentional, opening up new formulation possibilities to increase the solubility and bioavailability of poorly soluble active molecules, or to protect fragile biomolecules. The physical properties of amorphous and glassy states are highly specific and differ from those of the crystalline state. In view of strict regulatory requirements, knowledge of these states has become indispensable for mastering the formulation of solid drug forms. A general and fairly detailed presentation of their properties was given in the article
Advantages of the amorphous form
The use of the amorphous form of solid Active Pharmaceutical Ingredients (APIs) – and in particular those with low solubility in aqueous biological fluids – is one of the most effective approaches for significantly increasing their solubility and bioavailability. Unlike the action of solubilizing agents, which merely push back the solubility limit of the crystalline form and may also modify membrane permeability, "dissolution" of an amorphous form leads to profound supersaturation relative to this limit and therefore to very high concentrations, even for the pure compound.
In the case of formulations based on very fragile biomolecules (proteins, vaccines), it is possible to increase their physical and chemical stability by intimately mixing the biomolecules with cryoprotectants (sugars, amino acids, polyols, etc.), provided these are in amorphous form. They can ensure structural immobilization of fragile molecules if their own molecular mobility is correctly adapted.
Difficulties of the amorphous form
The main pitfalls in using amorphous materials are their formation and physical stability. The conditions that enable us to obtain a glassy (i.e. solid amorphous) compound, and maintain...
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
The Ultimate Scientific and Technical Reference
KEYWORDS
stability | amorphous | solubility | glass transition
This article is included in
Drugs and pharmaceuticals
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Amorphous and glassy states of molecular and pharmaceutical compounds
Bibliography
Bibliography
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
The Ultimate Scientific and Technical Reference